

Amendments to the Specification:

Paragraph [0054] incorrectly lists Sarafotoxin 56c as an endothelin B (ET_B) antagonist when this compound is an ET_B agonist. To correct this error, please replace paragraph [0054] with the following replacement paragraph that removes Sarafotoxin 56c from the non-limiting list of ET_B antagonists.

[0054] Examples of ET_B antagonists useful in the present invention include, but are not limited to, atrasentan, tezosentan, bosentan, sitaxsentan, enrasentan, Ro468443, TBC10950, TBC10894, A192621, A308165, SB209670, SB217242, A182086, (s)-Lu302872, J-104132, TAK-044, IRL2500, RES7011, Aselacins A, B, and C, Ro470203, Ro462005, sulfamethoxazole, cochinmicin I, II, and III, L749329, L571281, L754142, J104132, CGS27830, A182086, PD142893, PD143296, PD145065, PD156252, PD159020, PD160672, PD160874, TM-ET-1, IRL3630, Ro485695, L753037, LU224332, PD142893, LU302872, PD145065, Ro610612, SB217242, BQ788, and mixtures thereof. BQ-788 is a preferred specific endothelin B antagonist, and is the sodium salt of N-cis-2,6-dimethylpiperidinocarbonyl-L-gamma-me-thylleucyl-D-1-methoxycarbonyl triptophanyl-DNle (see Proc. Natl. Acad. Sci. USA, 91:4892-4896 (1994)).